Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China

Purpose We aim to assess whether osimertinib postoperative adjuvant therapy, compared with placebo, is cost-effective in China. Methods We set up the Markov model that contains three health states over a 20-year period. Data were collected from the ADAURA trial that included transition probabilities and safety data. Through the analysis of literature and local charges, we explore both the cost and utility values. Sensitivity analyses were employed using TreeAge Pro software to access model stability. Findings Patients in the osimertinib group had 1.46 more Quality-adjusted Life Years (8.45 QALYs vs 6.99 QALYs) than the placebo group at an incremental cost of $14098.51($39962.99 vs $25864.48). Compared with the placebo group, the treatment strategy with osimertinib postoperative adjuvant therapy had an incremental cost-effectiveness ratio of $9661.97/QALY. The probability of the osimertinib-assisted therapy strategy being cost-effective will reach 100% if the threshold of willingness to pay is above $15,000/QALY. Implications From the perspective of the Chinese Healthcare System, the treatment strategy with osimertinib postoperative adjuvant therapy is more cost-effective than the placebo strategy.

Automated summary

This study aims to evaluate the cost-effectiveness of osimertinib postoperative adjuvant therapy in China. A Markov model was constructed using data from the ADAURA trial. The results showed that compared to placebo, patients in the osimertinib group had a higher quality-adjusted life year (QALY) gain and a higher cost-effectiveness ratio.